MORGAN STANLEY PLC/CALL/MADRIGAL PHARMACEUTICALS/275/0.02/20.09.24 | Real-time Bid/Ask 10:11:32 16/07/2024 pm IST | ||
| 0.62 EUR / 0.72 EUR | +9.84% |
|
| Current month | -8.96% | ||
| 1 month | -10.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about MADRIGAL PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 16/24/16 | 0.63 | +3.28% |
| 15/24/15 | 0.61 | -12.86% |
| 12/24/12 | 0.7 | -9.09% |
| 11/24/11 | 0.77 | 0.00% |
| 10/24/10 | 0.77 | -3.75% |
Delayed Quote Börse Stuttgart
Last update July 16, 2024 at 09:02 pm IST
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | MADRIGAL PHARMACEUTICALS, INC. |
| Issuer | Morgan Stanley |
| WKN | ME9H25 |
| ISIN | DE000ME9H254 |
| Date issued | 01/03/2024 |
| Strike | 275 $ |
| Maturity | 20/09/2024 (66 Days) |
| Parity | 50 : 1 |
| Emission price | 1.01 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.49 € |
|---|---|
| Lowest since issue | 0.158 € |
| Spread | 0.1 € |
| Spread % | 14.08% |
Company Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
Consensus: Madrigal Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
280
USD
Average target price
365.3
USD
Spread / Average Target
+30.50%
- Stock Market
- Warrants
- Warrant
